Atossa Therapeutics Other 8-K Filing
Atossa Therapeutics announced a plan to issue one contingent value right (CVR) for each share of common stock, allowing shareholders to receive 25% of net proceeds from the potential monetization of its first qualifying FDA rare pediatric disease priority review voucher. The CVR payments are subject to an aggregate cap of $50 million and are tied to the company's (Z)-endoxifen development programs. The CVRs will be 'stapled' to the common stock and will not trade separately.
- Term
- through Dec 31, 2036